Melola Discovery

← Melola Discovery

Jurnal SINTA 1

Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial

ACTA MEDICA INDONESIANA · Vol. 56 No. 3 (2024)

ISSN
2338-2732, 0125-9326
Terbit
2024-10-25
Penerbit
The Indonesian Society of Internal Medicine
Bahasa
eng

Abstrak

Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2DM. Methods: A 12-week double-blind, randomized, placebo-controlled clinical trial was conducted with 104 eligible participants. They were assigned to receive DLBS3233 or a placebo along with lifestyle modifications. Various metabolic parameters, including fasting and post-meal plasma glucose levels at two hours, fasting insulin level, HOMA-IR, adiponectin level, lipid profile, superoxide dismutase (SOD) activity, GLUT-4 concentrations, and body weight measurements, were assessed at baseline, Week 6, and Week 12. Safety parameters assessment will include vital signs, liver function, renal function and adverse event. Results: Participants exhibited similar demographic characteristics in both groups. While no significant changes were noted in fasting plasma glucose and most other parameters, the DLBS3233 group significantly reduced 2-hour postprandial glucose at Week 12 (p = 0.026). There were no substantial differences in A1c levels, fasting insulin, insulin resistance, adiponectin levels, or lipid profiles between the two groups at any point in time. Safety parameters, including blood pressure, liver enzymes, heart rate, gamma GT, and serum creatinine, remained comparable between the groups. Conclusion: DLBS3233 showed potential for improving postprandial glucose control in newly diagnosed T2DM individuals. Although significant changes were limited, the study suggests that DLBS3233 could enhance glycemic regulation. The safety evaluation indicated no adverse effects on vital parameters. Further research with larger samples and more prolonged duration is warranted to comprehensively explore DLBS3233’s potential in T2DM management.

Kata kunci

Jaringan kolaborasi para penulis

39 penulis · 226 tautan kepenulisan bersama

Arahkan kursor atau ketuk sebuah nama untuk menyorot rekan penulisnya. Klik dua kali untuk membuka halaman penulis.

  • Universitas Halu Oleo
  • Afiliasi tidak diketahui
  • Organisasi berbeda
  • Organisasi sama
  • Afiliasi tidak diketahui
  • Garis lebih tebal = lebih banyak artikel bersama · lingkaran lebih besar = lebih banyak artikel
Tampilkan sebagai tabel
Rekan penulisOrganisasiArtikel bersama
Hasbudin HasbudinAfiliasi tidak diketahui1
Tuti DharmawatiAfiliasi tidak diketahui1
Nur AsyikUniversitas Halu Oleo1
Tamrin TamrinAfiliasi tidak diketahui1
Darmono DarmonoAfiliasi tidak diketahui1
Tjokorda Gde Dalem PemayunAfiliasi tidak diketahui1
Banundari RachmawatiAfiliasi tidak diketahui1
Samsuridjal DjauziAfiliasi tidak diketahui1
Wismandari WisnuAfiliasi tidak diketahui1
Iris RengganisAfiliasi tidak diketahui1
Alvina WidhaniAfiliasi tidak diketahui1
Anshari Saifuddin HasibuanAfiliasi tidak diketahui1
Sukamto KoesnoeAfiliasi tidak diketahui1
Suzy MariaAfiliasi tidak diketahui1
Andi Makbul AmanAfiliasi tidak diketahui1
Hendra ZufryAfiliasi tidak diketahui1
Ketut SuastikaAfiliasi tidak diketahui1
Cissy KartasasmitaAfiliasi tidak diketahui1
Ida Ayu KshantiAfiliasi tidak diketahui1
Erwanto Budi WinulyoAfiliasi tidak diketahui1
Hindra IrawanAfiliasi tidak diketahui1
Nanny SoetedjoAfiliasi tidak diketahui1
Sobagijo AdiAfiliasi tidak diketahui1
Nabilla GitaAfiliasi tidak diketahui1
Diana Nur AfifahAfiliasi tidak diketahui1
MAGGY THENAWIDJAJA SUHARTONOAfiliasi tidak diketahui1
Laurentia StephaniAfiliasi tidak diketahui1
Yanti LimAfiliasi tidak diketahui1
Wangsa Tirta IsmayaAfiliasi tidak diketahui1

Afiliasi berasal dari OpenAlex; metadata OAI-PMH jurnal tidak memuatnya. Penulis tanpa ID OpenAlex dicocokkan berdasarkan nama, sehingga dua orang bisa tergabung atau satu orang bisa terpisah.

Sumber metadata: OAI-PMH (metadata jurnal) http://www.actamedindones.org/index.php/ijim/oai, pertama di-harvest 8 Nov 2026, terakhir terlihat 8 Nov 2026.
Metadata asli (oai_dc)
<oai_dc:dc xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en-US">Effectiveness and Safety of DLBS3233 in Newly Diagnosed Type 2 Diabetes Mellitus: A 12-week Clinical Trial</dc:title>
	<dc:creator>Nugroho, Heri</dc:creator>
	<dc:creator>Nurmilawati, Nurmilawati</dc:creator>
	<dc:creator>Novitasari, Diana</dc:creator>
	<dc:creator>Rombeallo, Lidia</dc:creator>
	<dc:creator>Effendi, Rambu Farah</dc:creator>
	<dc:creator>Reski, Reski</dc:creator>
	<dc:creator>Surayya, Intan</dc:creator>
	<dc:creator>Daryanto, Nugroho Agung</dc:creator>
	<dc:creator>Putera, Solomon</dc:creator>
	<dc:creator>Tjandrawinata, Raymond Rubianto</dc:creator>
	<dc:subject xml:lang="en-US">Type 2 Diabetes Mellitus</dc:subject>
	<dc:subject xml:lang="en-US">DLBS3233</dc:subject>
	<dc:subject xml:lang="en-US">Insulin sensitivity</dc:subject>
	<dc:subject xml:lang="en-US">clinical trial</dc:subject>
	<dc:subject xml:lang="en-US">diabetes</dc:subject>
	<dc:description xml:lang="en-US">Background: DLBS3233, recognized as an agent enhancing insulin sensitivity, has exhibited promise as a therapeutic option for addressing type 2 diabetes mellitus (T2DM). This study aimed to evaluate the effectiveness and safety of DLBS3233, a natural compound, in individuals newly diagnosed with T2DM. Methods: A 12-week double-blind, randomized, placebo-controlled clinical trial was conducted with 104 eligible participants. They were assigned to receive DLBS3233 or a placebo along with lifestyle modifications. Various metabolic parameters, including fasting and post-meal plasma glucose levels at two hours, fasting insulin level, HOMA-IR, adiponectin level, lipid profile, superoxide dismutase (SOD) activity, GLUT-4 concentrations, and body weight measurements, were assessed at baseline, Week 6, and Week 12. Safety parameters assessment will include vital signs, liver function, renal function and adverse event. Results: Participants exhibited similar demographic characteristics in both groups. While no significant changes were noted in fasting plasma glucose and most other parameters, the DLBS3233 group significantly reduced 2-hour postprandial glucose at Week 12 (p = 0.026). There were no substantial differences in A1c levels, fasting insulin, insulin resistance, adiponectin levels, or lipid profiles between the two groups at any point in time. Safety parameters, including blood pressure, liver enzymes, heart rate, gamma GT, and serum creatinine, remained comparable between the groups. Conclusion: DLBS3233 showed potential for improving postprandial glucose control in newly diagnosed T2DM individuals. Although significant changes were limited, the study suggests that DLBS3233 could enhance glycemic regulation. The safety evaluation indicated no adverse effects on vital parameters. Further research with larger samples and more prolonged duration is warranted to comprehensively explore DLBS3233’s potential in T2DM management.</dc:description>
	<dc:publisher xml:lang="en-US">The Indonesian Society of Internal Medicine</dc:publisher>
	<dc:date>2024-10-25</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>http://www.actamedindones.org/index.php/ijim/article/view/2621</dc:identifier>
	<dc:source xml:lang="en-US">Acta Medica Indonesiana; Vol. 56 No. 3 (2024): Acta Medica Indonesiana; 291</dc:source>
	<dc:source>2338-2732</dc:source>
	<dc:source>0125-9326</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>http://www.actamedindones.org/index.php/ijim/article/view/2621/pdf</dc:relation>
	<dc:rights xml:lang="en-US">Copyright (c) 2024 Heri Nugroho, Nurmilawati Nurmilawati, Diana Novitasari, Lidia Rombeallo, Rambu Farah Effendi, Mellisa Kurniawati, Reski Reski, Intan Surayya, Nugroho Agung Daryanto, Solomon Putera, Raymond Rubianto Tjandrawinata</dc:rights>
</oai_dc:dc>